ADOCIA a biotechnology company dedicated to protein delivery

  • Contact Us
  • Linkedin
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Spontaneous application
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

Press Releases 

  • General News
  • Financial News

2019

Download
2019/10/22 Adocia Announces Third Quarter 2019 Financial Results Adobe_PDF_Icon.svg
2019/10/14 Adocia obtains additional financial resources to accelerate its growth Adobe_PDF_Icon.svg
2019/09/30 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case Adobe_PDF_Icon.svg
2019/09/10 Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD Adobe_PDF_Icon.svg
2019/08/23 Adocia announces the decision of the American Arbitration Association Tribunal Adobe_PDF_Icon.svg
2019/07/17 Adocia Presents First Half 2019 Financial Results Adobe_PDF_Icon.svg
2019/06/06 Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes Adobe_PDF_Icon.svg
2019/06/04 Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions Adobe_PDF_Icon.svg
2019/04/15 Adocia announces the release of its Reference Document for the year 2018 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces first quarter 2019 financial results: cash position and revenue Adobe_PDF_Icon.svg
2019/04/10 Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin Adobe_PDF_Icon.svg
2019/04/10 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris Adobe_PDF_Icon.svg
2019/03/13 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position Adobe_PDF_Icon.svg
2019/02/12 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 Adobe_PDF_Icon.svg
2019/01/16 Adocia confirms its financial calendar for 2019 Adobe_PDF_Icon.svg
2019/01/03 PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas Adobe_PDF_Icon.svg

2018

Download
2018/12/20 Adocia announces its financial calendar for 2019 Adobe_PDF_Icon.svg
2018/10/23 Adocia Announces Third Quarter 2018 Financial Results Adobe_PDF_Icon.svg
2018/10/11 Adocia informs about a civil action filed by Eli Lilly Adobe_PDF_Icon.svg
2018/10/05 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon Adobe_PDF_Icon.svg
2018/09/26 Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) Adobe_PDF_Icon.svg
2018/09/05 Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Adobe_PDF_Icon.svg
2018/08/30 Adocia Announces Update to Second Arbitration Against Eli Lilly & Company Adobe_PDF_Icon.svg
2018/08/21 Number of shares and voting rights of ADOCIA as of July 31, 2018 Adobe_PDF_Icon.svg
2018/08/08 American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly Adobe_PDF_Icon.svg
2018/07/25 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/07/18 Adocia Presents First Half 2018 Financial Results Adobe_PDF_Icon.svg
2018/06/14 Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions Adobe_PDF_Icon.svg
2018/06/05 Adocia to Participate in the Jefferies 2018 Global Healthcare Conference Adobe_PDF_Icon.svg
2018/06/01 Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine Adobe_PDF_Icon.svg
2018/05/02 Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao Adobe_PDF_Icon.svg
2018/04/26 Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. Adobe_PDF_Icon.svg
2018/04/19 Adocia announces the release of its Reference Document for the year 2017 Adobe_PDF_Icon.svg
2018/04/16 Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Adobe_PDF_Icon.svg
2018/04/16 Adocia announces first quarter 2018 financial results: Cash position and revenue Adobe_PDF_Icon.svg
2018/04/09 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Adobe_PDF_Icon.svg
2018/03/19 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Adobe_PDF_Icon.svg
2018/02/09 Adocia to Present at the 2018 BIO CEO & Investor Conference in New York Adobe_PDF_Icon.svg
2018/02/06 Adocia Files Additional Arbitration Claims Against Eli Lilly & Company Adobe_PDF_Icon.svg
2018/01/25 Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2018/01/08 Adocia announces its financial calendar for 2018 Adobe_PDF_Icon.svg
2018/01/04 Adocia announces expanded use of BioChaperone® beyond diabetes Adobe_PDF_Icon.svg

2017

Download
2017/12/06 Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes Adobe_PDF_Icon.svg
2017/11/20 Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study Adobe_PDF_Icon.svg
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/05 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes Adobe_PDF_Icon.svg
2017/07/26 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/06/07 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/06 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/01 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Adobe_PDF_Icon.svg
2017/06/01 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Adobe_PDF_Icon.svg
2017/05/30 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Adobe_PDF_Icon.svg
2017/05/30 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/02/13 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Adobe_PDF_Icon.svg
2017/01/27 Adocia to hold conference call on Monday January 30, 2017 Adobe_PDF_Icon.svg
2017/01/27 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Adobe_PDF_Icon.svg
2017/01/25 Adocia to hold conference call providing an update on its programs Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/05 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/12/16 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Adobe_PDF_Icon.svg
2016/11/10 Adocia to Participate in Upcoming Investor Conferences Adobe_PDF_Icon.svg
2016/11/07 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Adobe_PDF_Icon.svg
2016/10/27 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/09/22 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Adobe_PDF_Icon.svg
2016/09/20 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/09/19 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Adobe_PDF_Icon.svg
2016/09/08 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Adobe_PDF_Icon.svg
2016/09/07 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Adobe_PDF_Icon.svg
2016/08/25 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/07/05 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2016/06/08 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Adobe_PDF_Icon.svg
2016/06/06 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Adobe_PDF_Icon.svg
2016/06/02 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Adobe_PDF_Icon.svg
2016/05/31 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/25 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/03/14 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/02/04 Adocia to Present at the 2016 Leerink Global Healthcare Conference Adobe_PDF_Icon.svg
2016/01/29 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/12/11 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Adobe_PDF_Icon.svg
2015/11/25 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/11/19 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Adobe_PDF_Icon.svg
2015/11/04 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Adobe_PDF_Icon.svg
2015/09/30 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/08/27 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/10 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo Adobe_PDF_Icon.svg
2015/06/26 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/28 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Adobe_PDF_Icon.svg
2015/05/26 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/29 Adocia is now integrated into the EnterNext Tech 40 Index Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/03/05 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/02/05 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Adobe_PDF_Icon.svg
2015/01/20 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/12/22 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Adobe_PDF_Icon.svg
2014/12/19 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/09/30 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry Adobe_PDF_Icon.svg
2014/09/09 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes Adobe_PDF_Icon.svg
2014/08/25 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/09 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/06/04 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Ultra Fast Lispro Clinical Results Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/26 Gerard Soula Interview – La bourse et la vie (Transcript) Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/03/17 Adocia: confirmation of positive clinical results Combo Adobe_PDF_Icon.svg
2014/02/26 Positive Clinical Results for Combo Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/28 Adocia strengthens its diabetic foot ulcer patent portfolio Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg
2014/01/06 Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin Adobe_PDF_Icon.svg

2013

Download
2013/12/09 Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors Adobe_PDF_Icon.svg
2013/11/13 Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog Adobe_PDF_Icon.svg
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/10/19 Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/29 Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/18 Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/10/22 Adocia is extending its intellectual property to new formulations of monoclonal antibodies Adobe_PDF_Icon.svg
2012/10/01 EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany Adobe_PDF_Icon.svg
2012/09/12 Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde Adobe_PDF_Icon.svg
2012/09/07 DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/09/02 WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon Adobe_PDF_Icon.svg
2012/06/13 Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/23 ADOCIA reports positive phase II clinical results Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg

2019

Download
2019/12/06 Number of shares and voting rights of ADOCIA as of November 30, 2019 Adobe_PDF_Icon.svg
2019/11/07 Number of shares and voting rights of ADOCIA as of October 31st, 2019 Adobe_PDF_Icon.svg
2019/10/22 Adocia Announces Third Quarter 2019 Financial Results Adobe_PDF_Icon.svg
2019/10/14 Adocia obtains additional financial resources to accelerate its growth Adobe_PDF_Icon.svg
2019/10/04 Number of shares and voting rights of ADOCIA as of September 30, 2019 Adobe_PDF_Icon.svg
2019/09/30 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case Adobe_PDF_Icon.svg
2019/09/09 Number of shares and voting rights of ADOCIA as of August 31, 2019 Adobe_PDF_Icon.svg
2019/08/06 Number of shares and voting rights of ADOCIA as of July 31st 2019 Adobe_PDF_Icon.svg
2019/07/17 Adocia Presents First Half 2019 Financial Results Adobe_PDF_Icon.svg
2019/07/11 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2019/07/05 Number of shares and voting rights of ADOCIA as of June 30, 2019 Adobe_PDF_Icon.svg
2019/06/11 Number of shares and voting rights of ADOCIA as of May 31, 2019 Adobe_PDF_Icon.svg
2019/05/07 Number of shares and voting rights of ADOCIA as of April 30, 2019 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces the release of its Reference Document for the year 2018 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces first quarter 2019 financial results: cash position and revenue Adobe_PDF_Icon.svg
2019/04/10 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris Adobe_PDF_Icon.svg
2019/04/04 Number of shares and voting rights of ADOCIA as of March 31, 2019 Adobe_PDF_Icon.svg
2019/03/13 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position Adobe_PDF_Icon.svg
2019/03/08 Number of shares and voting rights of ADOCIA as of February 28, 2019 Adobe_PDF_Icon.svg
2019/02/12 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 Adobe_PDF_Icon.svg
2019/02/08 Number of shares and voting rights of ADOCIA as of January 31, 2019 Adobe_PDF_Icon.svg
2019/01/16 Adocia confirms its financial calendar for 2019 Adobe_PDF_Icon.svg
2019/01/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2019/01/10 Number of shares and voting rights of ADOCIA as of December 31, 2018 Adobe_PDF_Icon.svg

2018

Download
2018/12/20 Adocia announces its financial calendar for 2019 Adobe_PDF_Icon.svg
2018/12/06 Number of shares and voting rights of ADOCIA as of November 30, 2018 Adobe_PDF_Icon.svg
2018/11/07 Number of shares and voting rights of ADOCIA as of October 31, 2018 Adobe_PDF_Icon.svg
2018/10/23 Adocia Announces Third Quarter 2018 Financial Results Adobe_PDF_Icon.svg
2018/10/05 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon Adobe_PDF_Icon.svg
2018/10/04 Number of shares and voting rights of ADOCIA as of September 30, 2018 Adobe_PDF_Icon.svg
2018/09/06 Number of shares and voting rights of ADOCIA as of August 31, 2018 Adobe_PDF_Icon.svg
2018/08/21 Number of shares and voting rights of ADOCIA as of July 31, 2018 Adobe_PDF_Icon.svg
2018/07/25 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/07/18 Adocia Presents First Half 2018 Financial Results Adobe_PDF_Icon.svg
2018/07/04 Number of shares and voting rights of ADOCIA as of June 30, 2018 Adobe_PDF_Icon.svg
2018/06/08 Number of shares and voting rights of ADOCIA as of May, 31 2018 Adobe_PDF_Icon.svg
2018/05/07 Number of shares and voting rights of ADOCIA as of April, 30 2018 Adobe_PDF_Icon.svg
2018/04/19 Adocia announces the release of its Reference Document for the year 2017 Adobe_PDF_Icon.svg
2018/04/16 Number of shares and voting rights of ADOCIA as of March, 31 2018 Adobe_PDF_Icon.svg
2018/04/16 Adocia announces first quarter 2018 financial results: Cash position and revenue Adobe_PDF_Icon.svg
2018/04/09 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Adobe_PDF_Icon.svg
2018/03/19 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Adobe_PDF_Icon.svg
2018/03/16 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2018/03/06 Number of shares and voting rights of ADOCIA as of February 28, 2018 Adobe_PDF_Icon.svg
2018/02/12 Number of shares and voting rights of ADOCIA as of January 31, 2018 Adobe_PDF_Icon.svg
2018/02/12 Adocia: additional resources allocated to the liquidity agreement Adobe_PDF_Icon.svg
2018/01/10 Number of shares and voting rights of ADOCIA as of December 31, 2017 Adobe_PDF_Icon.svg
2018/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/01/08 Adocia announces its financial calendar for 2018 Adobe_PDF_Icon.svg

2017

Download
2017/12/07 Number of shares and voting rights of ADOCIA as of November 30, 2017 Adobe_PDF_Icon.svg
2017/11/08 Number of shares and voting rights of ADOCIA as of October 31, 2017 Adobe_PDF_Icon.svg
2017/10/12 Number of shares and voting rights of ADOCIA as of September 30, 2017 Adobe_PDF_Icon.svg
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/18 Number of shares and voting rights of ADOCIA as of August 31, 2017 Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/07/11 Number of shares and voting rights of ADOCIA as of June 30, 2017 Adobe_PDF_Icon.svg
2017/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2017/06/09 Number of shares and voting rights of ADOCIA as of May 31, 2017 Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/06 Half year report on Adocia’s liquidity agreement with Kepler Chevreux Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Adobe_PDF_Icon.svg
2015/10/05 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Adobe_PDF_Icon.svg
2015/09/17 ADOCIA: additional contribution to the liquidity agreement Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/07 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/29 2014 Financial Calendar Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg

2013

Download
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/20 2012 Annual Results Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/09/24 Large & Midcap Event – 24-25 September 2012, Paris Adobe_PDF_Icon.svg
2012/09/04 SFAF meeting – Half year 2012 results. At 14:30, NYSE EURONEXT, room Auditorium – 3 rue Cambon – 75001 Paris Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg

News

  • Press Releases
  • Upcoming Events

A la Une / Spotlight

  • Adocia-Analyse Department

    France 3 Auvergne Rhône Alpes (French TV) broadcast: Adocia develops faster, more physiologic insulins to improve the lives of people with diabetes. Eve-Marie, T1D, shares her daily life struggles and her hopes for improved life with diabetes.

    In France, more than 3.5 million people live wi...
  • Gérard Soula, Adocia CEO

    BFM TV Broadcast in Adocia laboratory on World Diabetes Day: “Diabetes, an omnipresent disease which now affects one in eleven people worldwide”

    On World Diabetes Day, BFM TV highlighted “the ...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP
Cookies

ADOCIA uses cookies for the effective operation of the Site and to monitor and analyze the traffic on the Site.
The information collected through cookies is solely and strictly for ADOCIA, in compliance with the regulation applicable to the protection of personal data. They are never transmitted to third-parties.